Research programme: erythropoietin mimetics - Locus PharmaceuticalsAlternative Names: EPO mimetics - Locus
Latest Information Update: 10 May 2007
At a glance
- Originator Locus Pharmaceuticals
- Class Small molecules
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 27 Feb 2003 Preclinical trials in Anaemia in USA (PO)